Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
← catalyst calendarNCT07155226 · readout in 911 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
84estimated
Sites
30
Countries
Australia, Canada, Denmark +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-09 | actual | When the study began enrolling |
| Primary completion | 2029-02-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-02-15 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Acute Lymphoblastic Leukaemia
- Acute Myeloid Leukaemia
- Higher-risk Myelodysplastic Syndromes
Interventions
- Drug: AZD3632
- Drug: Posaconazole
Primary outcomes
what the primary-completion date above is the date OFModule 1: Number of participants with dose-limiting toxicity (DLT)
measured At the end of Cycle 1 (each cycle is 28 days)
Module 1 and Module 2: Number of participants with dose modification, delay and discontinuations due to adverse events (AEs)
measured Up to 3 years 1 month
Module 1 and Module 2: Number of participants with treatment-emergent adverse events (TEAEs), treatment-related AEs (TRAEs) and serious adverse vents (SAEs)
measured Up to 30 days after last dose (approximately 3 years 1 month)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed